Pfizer Inc. (PFE)

Pfizer's stock price has been influenced by several key events in the past six months. On September 30, 2025, Pfizer's stock surged after announcing a drug pricing deal with the U.S. government, including drug price cuts and a commitment to invest in U.S. research and manufacturing. Additionally, Pfizer's acquisition of Metsera contributed to investor confidence. Earlier in the year, Pfizer's first-quarter 2024 revenues reflected a decline due to decreased revenues from COVID-related products, but the company delivered strong performance in its non-COVID product portfolio and raised its adjusted EPS guidance for full-year 2024.

Demand seasonality for Pfizer Inc.'s products and services is particularly evident in its COVID-related offerings, with approximately 90% of its COVID-related product sales anticipated in the second half of the year, mostly in the fourth quarter. While the overall demand for COVID-19 vaccines and treatments has declined, the seasonal pattern for remaining demand is still observed. Beyond COVID-19 products, the general pharmaceutical market can experience some seasonality, often linked to seasonal illnesses or healthcare spending cycles.

Pfizer Inc. is a multinational pharmaceutical and biotechnology corporation headquartered in New York City, founded in 1849. It operates within the Health Technology sector, specifically in the Pharmaceuticals: Major industry, and is a research-based biopharmaceutical entity involved in discovering, developing, manufacturing, marketing, selling, and distributing medicines and vaccines globally. Pfizer's products address various therapeutic areas, including anti-infectives, oncology, cardiovascular disease, diabetes, obesity, inflammation, immunology, rare diseases, and bacterial infections.

Pfizer Inc. has a significant global presence, operating in approximately 200 countries and territories, categorized into the United States, Developed Markets, and Emerging Markets. The company maintains 37 manufacturing sites worldwide, including 11 in the U.S. and major international facilities in countries such as Belgium, Germany, India, Ireland, Italy, Japan, Singapore, and France.

Pfizer's brand reputation has seen significant shifts, particularly during the COVID-19 pandemic, which improved public perception of pharmaceutical companies. Pfizer's announcement of its vaccine's high efficacy rate boosted its reputation, leading to a brand refresh in January 2021. However, recent challenges, including a corporate restructuring and the near-total loss of its 2022 acquisition of Global Blood Therapeutics, have impacted its reputation. Despite these headwinds, Pfizer's strong quarterly performances and focus on research and development are seen as positioning the company for a turnaround.

Pfizer Inc. is largely controlled by institutional shareholders, who collectively own about 65.26% to 70% of the company. Retail investors hold approximately 34.47% of the shares, while Pfizer insiders own about 0.27%. Major institutional shareholders include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Top individual/insider shareholders include Albert Bourla, Mikael Dolsten, and Douglas Lankler.